Market Share And Switching Dynamics Between Etanercept And Its Biosimilar Product In Sweden And Germany: A Real-World Preliminary Analysis

OBJECTIVES: To describe the market share and switching dynamics between etanercept innovator (Etnl) and its biosimilar (EtnBS) indicated for rheumatic diseases, in Germany and Sweden. METHODS: Patients receiving rheumatologists' prescriptions for Etnl and EtnBS in November 2015-March 217 were r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A565-A566
Hauptverfasser:	Alten, R, Neregård, P, Jones, HE, Meng, T, Curiale, C, Singh, E, Lucchese, L, Gossen, N, Bergman, GJ, Miglio, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological products Etanercept Market shares Medical treatment National health insurance Patients Penetration Prescription drugs Rheumatic diseases Rheumatologists
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!